Lesaka Technologies COO forfeits 68,319 shares

Lesaka Technologies (LSAK) reported its first GAAP profit since 2022, with FY26 revenue up 20% to ZAR6.33B, adjusted EBITDA up 41% to ZAR1.27B, and adjusted EPS up 210% to ZAR6.51. Consumer and enterprise divisions grew strongly, while the merchant division struggled. The company expects FY2027 costs to rise to ZAR350M, impacting near-term profitability. Management discussed M&A plans, deposit growth, and merchant segment challenges during the earnings call.

Lesaka Technologies Inc reported FY 2026 revenue of $721.6M, up 9.4% YoY, and net income of $2.8M, reversing a $91M loss from FY 2025. Growth was driven by consumer lending, insurance, and new business segments. The company launched a unified brand and exited non-core assets.

Lesaka Technologies reported a 9% revenue increase to $721.6M and net income of $2.8M, driven by Consumer and Enterprise growth, improved capital structure, and acquisitions. The company noted internal control weaknesses and regulatory risks, while the Bank Zero acquisition is expected to boost funding and growth.

LESAKA TECHNOLOGIES INC (LSAK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lesaka's FY2026 Results: Lesaka delivers FY2026 guidance across all metrics, exceeds Adjusted EPS range and achieves GAAP profitability JOHANNESBURG, September 9, 2026 - Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) today released results for the fourth quarter

Raymond James upgraded Hess Midstream Partners (HESM) to Outperform with a $32 price target, citing attractive valuation post-Chevron restructuring. The firm noted a 10.7% yield on expected 2027 distributions. HESM reported strong Q2 2026 earnings, but JPMorgan and Morgan Stanley downgraded it, citing contract and growth concerns. HESM trades at $30.04, near its 52-week low.

Piper Sandler downgraded Globe Life (NYSE:GL) to Neutral, lowering its price target to $165 from $200 due to concerns over medical claims volatility. The stock trades at $168.41 with a P/E ratio of 10.97. Q3 results showed revenue of $1.6B, beating estimates, but EPS missed at $4.84. The firm cited exposure to medical claims severity and irregularity in Medicare supplement claims as key issues.